Recombinant Human T-cell surface glycoprotein CD1a (CD1A)

What is the structural characterization of CD1a and how does it differ from other CD1 family members?

CD1a belongs to the CD1 family of cell-surface glycoproteins that present lipid antigens to T cells. Humans express five CD1 isoforms that fall into three groups based on sequence homology and immune functions. CD1a (group 1) is structurally distinguished by the small volume of its antigen-binding groove and its stunted A′ pocket . Unlike MHC molecules which show extensive polymorphism, CD1 molecules are highly conserved and show limited allelic polymorphism .

The antigen-binding cleft of CD1a comprises the A′- and F′-pockets, with the A′-pocket functioning as a molecular ruler, preferentially accommodating acyl chains between C18-23 in length . This unique structural characteristic influences the range of lipid antigens CD1a can present and the manner in which T cell receptors interact with the CD1a-lipid complex.

What are the expression patterns of CD1a in human tissues?

CD1a demonstrates a highly specific expression pattern, being predominantly and exclusively expressed on Langerhans cells in the epidermis . This expression pattern is significant for understanding CD1a's role in skin immunity and inflammatory skin disorders. CD1a-expressing dendritic cells are also located in non-skin tissues, suggesting potential roles for CD1a in pulmonary disorders and cancer beyond skin pathologies .

Unlike other immune recognition molecules, CD1a is expressed in humans but lacking in mice, which has historically limited in vivo functional studies . This species-specific expression pattern necessitates specialized experimental models, such as human CD1a-transgenic mice, to study CD1a function in vivo .

How does CD1a traffic within cells and how does this impact its function?

CD1a exhibits a distinct intracellular trafficking pathway, localizing primarily in early endosomal and recycling intracellular compartments . This trafficking pattern differs from other CD1 family members and influences the repertoire of lipid antigens that CD1a can acquire and present.

The unique trafficking pattern enables CD1a to sample lipid antigens from different cellular compartments, particularly those accessible through the early endosomal pathway. This trafficking pathway is critical for CD1a's ability to present both self-derived and foreign lipid antigens to T cells, influencing immune responses in various contexts, including inflammatory skin disorders and infection responses .

What methodologies are most effective for producing recombinant CD1a proteins for structural and functional studies?

For structural and functional studies of CD1a, researchers typically employ bacterial expression systems for producing recombinant CD1a proteins. The following methodology has proven effective:

• Expression system selection: E. coli expression systems with appropriate signal peptides for periplasmic targeting are commonly used for CD1a heavy chain production.

• Protein refolding: After expression, CD1a heavy chains are refolded in vitro with human β2-microglobulin to form functional CD1a heterodimers.

• Lipid loading: To study CD1a-lipid interactions, purified CD1a proteins are incubated with specific lipid antigens of interest. For crystallography studies, lipids such as urushiol, sulfatide, and DDM have been successfully loaded onto CD1a .

• Quality assessment: Size-exclusion chromatography and functional binding assays with CD1a-restricted T cell receptors are essential for confirming proper folding and functionality of recombinant CD1a proteins.

For advanced studies, chimeric CD1 proteins have been engineered to investigate domain-specific functions. Examples include CD1ad (containing α1 and α2 domains of CD1a with α3 domain from CD1d) and CD1ca (containing α1 and α2 domains from CD1c with α3 domain from CD1a) . These chimeric proteins have been instrumental in determining the importance of specific domains for TCR recognition.

How do CD1a-restricted T cells recognize lipid antigens, and what experimental approaches can be used to study these interactions?

CD1a-restricted T cells exhibit three distinct modes of antigen recognition:

• Dual recognition: T-cell receptors bind to both the CD1a surface and the presented lipid antigen .

• CD1a-only recognition: T-cell receptors bind to CD1a itself without contacting the lipid (lipid-agnostic recognition), which activates the T cell .

• Inhibitory recognition: Bulky lipid motifs protrude from the antigen-binding groove, preventing TCR binding and potentially inhibiting autoreactive T-cell activation .

For studying these interactions, researchers can employ:

• Tetramer assays: CD1a-endo tetramers can detect autoreactive T cells without adding defined antigens . This approach has been crucial for isolating CD1a-restricted T cells from human samples.

• Surface Plasmon Resonance (SPR): This technique measures the binding kinetics and affinity between CD1a-lipid complexes and T cell receptors. For example, SPR studies revealed the CO3 γδ TCR binds CD1a with a KD of 16.1 ± 1 μM .

• Crystallography: X-ray crystallography has been instrumental in determining the structure of CD1a-lipid-TCR complexes. The crystal structure of CD1a-urushiol binary complex revealed that urushiol antigen spans from the A′- to the F′-pocket with the catechol headgroup and acyl chain positioned in an unexpected orientation .

• Mutational analysis: Systematic mutation of CD1a residues has helped identify critical binding sites for different TCRs. This approach revealed that different TCRs interact with CD1a through distinct mechanisms, with some depending on the α3-domain while others do not .

What are the challenges in developing CD1a transgenic mouse models, and how can these be overcome?

Since wild-type mice lack CD1a expression, human CD1a-transgenic mice have been developed to study CD1a function in vivo. These models face several challenges:

• Promoter selection: Ensuring appropriate tissue-specific expression that mimics human CD1a distribution, particularly on Langerhans cells.

• Proper interaction with mouse T cells: Human CD1a must properly interact with the mouse T cell compartment to generate physiologically relevant responses.

• Lipid antigen availability: Ensuring the presence of appropriate lipid antigens that can be loaded onto CD1a in the mouse environment.

These challenges can be addressed through:

• Use of human promoter elements: To ensure CD1a expression patterns similar to those in humans.

• Cross-validation with human samples: Comparative studies between mouse models and human samples help verify the physiological relevance of findings.

• Humanized mouse models: More advanced models incorporating human immune cells can provide more accurate representations of CD1a function.

Studies using human CD1a-transgenic mice have successfully demonstrated CD1a's vital role in skin inflammation in vivo, particularly in poison ivy dermatitis and psoriasis models . These models showed that CD1a promotes specific amplification of CD4 αβ T cells, especially those producing IL-17 and IL-22 (TH17 cells) .

How can researchers effectively isolate and characterize CD1a-restricted T cells from human samples?

Isolation and characterization of CD1a-restricted T cells require specialized methodologies:

• CD1a tetramer-based isolation:

  • Generate CD1a-endo tetramers (CD1a loaded with endogenous lipids)

  • Perform flow cytometric sorting of CD1a-endo tetramer+ T cells from peripheral blood mononuclear cells (PBMCs)

  • Further enrich by magnetic sorting of specific T cell populations (e.g., γδ T cells)

• Functional characterization:

  • Cytokine production profiling (particularly IL-17 and IL-22 for skin inflammatory responses)

  • Proliferation assays in response to CD1a-expressing antigen-presenting cells

  • TCR sequencing to determine clonal diversity and preferential V-region usage

• TCR transfer and reconstruction:

  • Clone TCRs from isolated CD1a-restricted T cells

  • Express in reporter cell lines or primary T cells through retroviral transduction

  • Test specificity using cell lines expressing CD1a loaded with various lipid antigens

These approaches have revealed that CD1a-restricted T cells are the most frequent CD1-restricted T cells in blood and participate in immune responses to bacterial infections and various skin disorders .

What lipid antigens are presented by CD1a, and how can researchers identify novel CD1a ligands?

CD1a presents a diverse range of lipid antigens from both self and foreign sources. Known ligands include:

To identify novel CD1a ligands, researchers can employ:

• Mass spectrometry-based approaches:

  • Extract lipids bound to CD1a by gentle elution while preserving unliganded CD1a

  • Perform lipidomic analysis to identify and characterize eluted lipids

  • Confirm the presence of specific lipids (e.g., urushiol m/z 317.24) by mass spectrometry

• Functional screening:

  • Test lipid fractions from tissues or pathogens for activation of CD1a-restricted T cell lines

  • Use CD1a blocking antibodies as controls to confirm CD1a-dependent responses

  • Examine T cell cytokine profiles in response to identified lipid candidates

• Structural validation:

  • Perform crystallography of CD1a in complex with candidate lipids

  • Map interactions between lipids and CD1a binding pockets (A′ and F′)

  • Analyze van der Waals contacts with residues of the α1-helix of CD1a

How do CD1a-restricted γδ T cells differ from αβ T cells in their recognition of CD1a, and what methods can distinguish their functions?

CD1a-restricted γδ T cells exhibit unique recognition patterns compared to αβ T cells:

• Recognition mechanisms:

  • γδ TCRs can bind CD1a regardless of the nature of the bound lipid

  • Some γδ TCRs (e.g., CO3) recognize CD1a through an "atypical sideways" approach, contacting the backside of the CD1a binding cleft and β2 microglobulin

  • Unlike αβ TCRs that typically dock above the antigen-binding groove, γδ TCRs can approach CD1a from different angles

• Structural requirements:

  • The Vδ1 chain appears critical for CD1a recognition in identified γδ TCRs

  • Specific residues like tyrosine at position 104 (Tyr104) within the CDR3γ loop may be essential for CD1a recognition

  • Different γδ TCRs may depend on different CD1a domains (some require the α3-domain while others do not)

To distinguish the functions of CD1a-restricted γδ vs. αβ T cells, researchers can use:

• Chain replacement experiments:

  • Replace Vγ or Vδ chains with those from other γδ TCRs

  • Test hybrid TCRs for CD1a binding to determine critical recognition elements

• Domain-specific CD1a mutations:

  • Create CD1a variants with mutations in different domains

  • Test how these mutations differentially affect γδ vs. αβ T cell recognition

• Chimeric CD1 proteins:

  • Use CD1ad and CD1ca chimeric proteins to assess the importance of different domains

  • Compare binding of γδ vs. αβ TCRs to these chimeras

How might targeting CD1a be exploited for treating inflammatory skin diseases?

CD1a plays a crucial role in several inflammatory skin disorders, making it a promising therapeutic target:

• Antibody-based approaches:

  • CD1a blocking antibodies have demonstrated efficacy in CD1a-transgenic mouse models of contact dermatitis

  • Anti-CD1a treatment reduced ear swelling to wild-type levels and abrogated infiltration of inflammatory granulocytes and IL-17-producing CD4 T cells

  • Antibody treatment does not deplete Langerhans cells but rather blocks CD1a function on their surface

• Lipid-based interventions:

  • Understanding the "lipid-agnostic" recognition mode of some CD1a-autoreactive T cells suggests that certain lipids might competitively inhibit autoreactive T cell activation

  • Lipids that protrude from the CD1a binding groove and block TCR access could serve as inhibitory compounds

• Targeting downstream cytokine pathways:

  • CD1a-restricted T cells often produce IL-17 and IL-22, suggesting that combined therapies targeting both CD1a and these cytokines might provide synergistic benefits in conditions like psoriasis

For researchers developing such approaches, assessing the specificity and off-target effects is critical, as CD1a is expressed on Langerhans cells that play diverse roles in skin immunity beyond inflammatory responses.

What are the current gaps in understanding CD1a biology, and what experimental approaches might address these?

Despite significant advances, several knowledge gaps remain in CD1a biology:

• Tissue-specific functions beyond skin:

  • While CD1a is primarily studied in skin, CD1a-expressing dendritic cells exist in other tissues

  • Research question: What is the role of CD1a in pulmonary disorders and cancer?

  • Approach: Use tissue-specific CD1a transgenic models and single-cell RNA sequencing to identify CD1a+ cells in different tissues and characterize their interacting T cell populations

• Evolutionary significance of CD1a absence in mice:

  • Understanding why CD1a was lost in mice but retained in humans may provide insights into its immunological importance

  • Approach: Comparative genomic studies across species and assessment of functional redundancy among CD1 family members

• Lipid antigen processing pathways:

  • How lipid antigens are processed and loaded onto CD1a in different cellular compartments remains incompletely understood

  • Approach: Use CRISPR screening to identify proteins involved in lipid processing and loading onto CD1a, followed by detailed biochemical characterization

• Integration with innate immune pathways:

  • How CD1a-restricted T cell responses integrate with other innate immune pathways in skin defense and inflammation

  • Approach: Multiplex imaging and systems biology approaches to map the interactome of CD1a+ cells in healthy and diseased tissues

Addressing these gaps will require interdisciplinary approaches combining structural biology, immunology, and advanced imaging techniques.

What are the optimal methods for detecting CD1a expression in different tissue samples?

Accurate detection of CD1a expression in tissues requires specific methodologies:

• Immunohistochemistry (IHC) and Immunofluorescence (IF):

  • Use validated anti-CD1a antibodies (clones O10 or HI149)

  • Include appropriate positive controls (skin sections containing Langerhans cells)

  • Implement antigen retrieval techniques (citrate buffer pH 6.0) to optimize staining

  • Counterstain with markers for dendritic cells (e.g., langerin/CD207 for Langerhans cells)

• Flow cytometry:

  • Fresh tissue digestion protocols optimized to preserve CD1a epitopes

  • Include live/dead discrimination to exclude autofluorescent dead cells

  • Use multiparameter panels including additional markers like CD1c, CD11c, and HLA-DR

• Molecular detection:

  • qRT-PCR with validated primers spanning CD1A exon junctions

  • RNA-seq analysis with appropriate normalization for tissue-specific gene expression

  • Single-cell RNA sequencing to identify CD1a-expressing cell populations at higher resolution

These methods should be selected based on specific research questions, considering that CD1a expression levels may vary across tissues and under different inflammatory conditions.

How can researchers effectively model CD1a-mediated diseases in experimental systems?

Modeling CD1a-mediated diseases requires specialized approaches due to its absence in conventional mouse models:

• Human CD1a-transgenic mouse models:

  • These models have successfully demonstrated CD1a's role in poison ivy dermatitis and psoriasis

  • Expression should be driven by appropriate promoters to recapitulate human CD1a distribution

  • Disease induction protocols include topical application of urushiol (for poison ivy model) or imiquimod (for psoriasis model)

• In vitro human skin models:

  • 3D organotypic skin cultures incorporating CD1a+ Langerhans cells

  • Patient-derived skin explants maintained in organ culture systems

  • Co-culture systems with isolated CD1a+ dendritic cells and autologous T cells

• Humanized mouse models:

  • NSG mice engrafted with human hematopoietic stem cells and skin grafts

  • May better recapitulate human immune responses involving CD1a

• Disease-specific readouts:

  • For inflammatory skin conditions: ear thickness measurements, histopathological scoring, and cytokine profiling

  • Flow cytometric quantification of infiltrating T cells, particularly IL-17 and IL-22-producing CD4+ T cells

  • Molecular imaging to track T cell migration and activation in response to CD1a-presented antigens

These experimental systems provide complementary insights and should be selected based on the specific aspects of CD1a biology being investigated.